Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
P/E ratio for Phathom Pharmaceuticals, Inc. (PHAT)
P/E ratio as of 2023: -2.32
According to Phathom Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.32. At the end of 2022 the company had a P/E ratio of -1.97.
P/E ratio history for Phathom Pharmaceuticals, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.32 |
| 2022 | -1.97 |
| 2021 | -4.91 |
| 2020 | -8.28 |
| 2019 | -3.67 |
| 2018 | -163.84 |